11-amino acid peptide imitating the structure of erythropoietin α-helix b improves endothelial function, but stimulates thrombosis in rats.

M. V. Korokin; Корокин М. В.; V. O. Soldatov; Солдатов В. О.; A. A. Tietze; Титце А. A.; M. V. Golubev; Голубев И. В.; A. E. Belykh; Белых А. Е.; M. V. Kubekina; Кубекина М. В.; O. A. Puchenkova; Пученкова О. А.; T. A. Denisyuk; Денисюк Т. А.; V. V. Gureyev; Гуреев В. В.; T. G. Pokrovskaya; Покровская Т. Г.; O. S. Gudyrev; Гудырев О. С.; M. A. Zhuchenko; Жученко М. А.; M. A. Zatolokina; Затолокина М. А.; M. V. Pokrovskiy; Покровский М. В.

doi:10.19163/2307-9266-2019-7-6-312-320

11-amino acid peptide imitating the structure of erythropoietin α-helix b improves endothelial function, but stimulates thrombosis in rats.

作者: Korokin M.V.¹, Soldatov V.O.¹, Tietze A.A.², Golubev M.V.¹, Belykh A.E.³, Kubekina M.V.⁴, Puchenkova O.A.¹, Denisyuk T.A.³, Gureyev V.V.¹, Pokrovskaya T.G.¹, Gudyrev O.S.¹, Zhuchenko M.A.⁵, Zatolokina M.A.³, Pokrovskiy M.V.¹
隶属关系:
1. Belgorod State National Research University
2. University of Gothenburg
3. Kursk State Medical University
4. Institute of Gene Biology of the Russian Academy of Sciences
5. Scientific Research Centre, Kurchatov Institute
期: 卷 7, 编号 6 (2019)
页面: 312-320
栏目: Articles
URL: https://ogarev-online.ru/2307-9266/article/view/111614
DOI: https://doi.org/10.19163/2307-9266-2019-7-6-312-320
ID: 111614

如何引用文章

全文:

详细
全文:
作者简介
参考
补充文件
统计

详细

The aim of the study was to test whether P-αB can be positioned as a preventing and treating agent for cardiovascular diseases.Materials and methods. The study was performed on sexually mature male Wistar rats. Endothelial dysfunction was modulated by a 7-days intraperitoneal administration of L-NAME at the dose of 2.5 mg/100 g. P-αB, or erythropoietin (EPO), was used for therapy at the dose of 2.5 µg/100 g × 3 times for 7 days, the total dose was 7.5 µg/100 g. The function of endothelium was estimated by an endothelium-dependent and endothelium-independent vasodilation. In addition, a histological assessment of the abdominal aortic wall state and the analysis of eNos, Tnf and Il-1β genes expression were performed. To estimate prothrombotic properties, P-αB and EPO were administered, at the doses of 2.5 and 5 µg/100 g (3 times a day for 7 days, the total doses were 7.5 µg/100 g and 15 µg/100 g, respectively) and on the 8th day, the time of ferric (III) chloride-induced carotid artery thrombosis was estimated.Results. Theresults of the functional tests for endothelium-dependent and endothelium-independent vasodilatation, as well as the histological picture of the aorta have evidenced that P-αB and EPO do not affect L-NAME-induced hypertension but improve the endothelium function. At the same time, P-αB shows a significantly higher endothelial-protective activity, reducing the coefficient of endothelial dysfunction from 5.1±0.15 to 2.72±0.12. In addition, P-αB has significantly increased the expression of eNos and reduced the expression level of Tnf and Il-1β mRNA genes. Carrying out Ferric (III) chloride-induced carotid artery thrombosis has revealed that P-αB (5 µg/100 g × 3 times a day for 7 days, total dose was 15 µg/100 g) has a lower but statistically significant prothrombotic activity than EPO.Conclusion. P-αB can be positioned as an atheroprotector because of its ability to prevent the death of endothelial cells, as well as to reduce remodeling and proinflammatory activation of the vascular wall. However, the prothrombotic properties of P-αB limit its use as a preventing and treating agent for atherosclerosis-associated diseases.

关键词

P-αB, atherosclerosis, erythropoietin, rats, P-αB, cibenitide, endothelium

全文:

##article.viewOnOriginalSite##

参考

Глушко А.А., Воронков А.В., Черников М.В. Молекулярные мишени для поиска веществ, обладающих эндотелиопротекторными свойствами (обзорная статья) // Биоорганическая химия. 2014. Т. 40. № 5. С. 515-527. doi: 10.7868/S0132342314050066.
Тюренков И.Н., Воронков А.В., Слиецанс А.А., Волотова Е. В. Эндотелиопротекторы новый класс фармакологических препаратов // Вестник Российской академии медицинских наук. 2012, Т. 67, №7. - С. 50-57. DOI: https://doi.org/10.15690/vramn.v67i7.341
Zárate A., Manuel-Apolinar L., Basurto L., De la Chesnaye E., Saldívar I. Cholesterol and atherosclerosis. Historical considerations and treatment // Arch Cardiol Mex. - 2016. - V. 86, N 2. - P. 163-9. doi: 10.1016/j.acmx.2015.12.002. Epub 2016 Jan 7.
Orekhov A.N., Poznyak A.V., Sobenin I.A., Nikifirov N.N., Ivanova E.A. Mitochondrion as a selective target for treatment of atherosclerosis: Role of mitochondrial DNA mutations and defective mitophagy in the pathogenesis of atherosclerosis and chronic inflammation // Curr Neuropharmacol. 2019. doi: 10.2174/1570159X17666191118125018.
Marzetti E., Calvani R., Cesari M., Buford T.W., Lorenzi M., Behnke B.J., Leeuwenburgh C. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials // Int J Biochem Cell Biol. - 2013. - V. 45, N 10. - P. 2288-301. doi: 10.1016/j.biocel.2013.06.024.
Воронков А. В., Поздняков Д. И., Мирошниченко К. А., Потапова А. А. Влияние новых производных пиримидина на вазодилатирующую функцию эндотелия сосудов головного мозга в условиях хронической травматической энцефалопатии // Экспериментальная и клиническая фармакология. 2019. Т. 82. № 11. С. 11-14. doi: 10.30906/0869-2092-2019-82-11-11-14.
Воронков А.В., Поздняков Д.И. Оценка влияния 4-гидрокси-3,5-ди-трет-бутилкоричной кислоты на изменения антитромботического потенциала эндотелия у кроликов в условиях ишемии головного мозга // Экспериментальная и клиническая фармакология. 2018. Т. 81. № 8. С. 3-7. doi: 10.30906/0869-2092-2018-81-8-3-7
Gimbrone M.A. Jr., García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis // Circ Res. - 2016. - V. 118, N 4. - P. 620-636. doi: 10.1161/CIRCRESAHA.115.306301.
Елагин, В.В. Подходы к коррекции ишемических и реперфузионных повреждений почек в эксперименте / В.В. Елагин, О.И. Братчиков, А.А. Ульянова // Научные результаты биомедицинских исследований. - 2018. - №4(3). - С. 63-69. doi: 10.18413/2313-89552018-4-3-0-6.
Shabelnikova A.S., Lutsenko V.D., Pokrovskii M.V., Peresipkina A.A., Korokin M.V., Gudyrev O.S., Hoshenko Y.A. Protective effects of recombinant erythropoietin in ischemia of the retina: The role of mechanisms of preconditioning // Research Journal of Medical Sciences. - 2015. - V. 9, N 4. - P. 200-203. doi: 10.3923/rjmsci.2015.200.203.
Корокина, Л.В. Фармакологическая коррекция L-NAME индуцированного дефицита оксида азота рекомбинантным эритропоэтином / Л.В. Корокина, И.М. Колесник, M.В. Покровский, М.В. Корокин, А.С. Белоус, Е.Б. Артюшкова, Т.Г. Покровская, О.С. Гудырев, А.Е. Королев, Л.А. Павлова, О.О. Новиков // Кубанский научный медицинский вестник. - 2009. - №9 (114). - С. 66-69.
Denisyuk T. Pharmacotherapeutic strategies for endothelial dysfunction correction with use of statins in syndrome of systemic inflammatory response // Research Results in Pharmacology. - 2017. - V. 3, N 4. - P. 35-77. doi: 10.18413/2313-8971-2017-3-4-35-77.
Денисюк, Т.А. Сочетанное применение рекомбинатного эритропоэтина и статинов при эндотоксининдуцированной эндотелиальной дисфункции / Т.А. Денисюк, М.В. Покровский // Аллергология и иммунология. - 2016. - №17(1). - С. 64-65.
Rajkumar D.S.R., Gudyrev O.S., Faiteison A.V., Pokrovskii M.V. Study of the microcirculation level in bone with osteoporosis and osteoporotic fractures during therapy with recombinant erythropoietin, rosuvastatin and their combinations // Research result: pharmacology and clinical pharmacology. -2015. - V. 4, N 6. - P. 57-60. doi: 10.18413/2313-8971-2015-1-4-57-60.
Souvenir R., Doycheva D., Zhang J.H., Tang J. Erythropoietin in stroke therapy: friend or foe // Curr Med Chem. - 2015. - V. 22, N 10. - P. 1205-13.
Pearl R.G. Erythropoietin and organ protecttion: lessons from negative clinical trials // Crit Care. -2014. - V. 18, N 5. - P. 526. doi: 10.1186/s13054-014-0526-9.
Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.W., Smart J., Su-Rick C.J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor // Proc Natl Acad Sci U S A. -2004. - V. 101, N 41. - P. 14907-12. doi.org/10.1073/pnas.0406491101.
Brines M., Patel N.S., Villa P., Brines C., Mennini T., De Paola M., Erbayraktar Z., Erbayraktar S., Sepodes B., Thiemermann C., Ghezzi P., Yamin M., Hand C.C., Xie Q.W., Coleman T., Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin // Proc Natl Acad Sci USA. - 2008. - V. 105, N 31. - P. 10925-30. doi: 10.1073/pnas.0805594105.
Sultan F., Singh T.U., Kumar T., Rungsung S., Rabha D.J., Vishwakarma A., Sukumaran S.V., Kandasamy A., Parida S. Shortterm exposure of erythropoietin impairs endothelial function through inhibition of nitric oxide production and eNOS mRNA expression in the rat pulmonary artery // Pharmacol Rep. -2017. - V. 69, N 4. - P. 658-665. doi: 10.1016/j.pharep.2017.02.003.
Pytela R., Pierschbacher M.D., Ginsberg M.H., Plow E.F., Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors // Science. -1986. - V. 231, N 4745. - P. 1559-62. doi: 10.1126/science.2420006.
Sheu J.R., Yen M.H., Peng H.C., Chang M.C., Huang T.F. Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments // Eur J Pharmacol. -1995. - V. 294, N 1. - P. 231-8. doi: 10.1016/0014-2999(95)00530-7.
Hung Y.C., Kuo Y.J., Huang S.S., Huang T.F. Trimucrin, an Arg-Gly-Asp containing disintegrin, attenuates myocardial ischemia-reperfusion injury in murine by inhibiting platelet function // Eur J Pharmacol. - 2017. - V. 813. - P. 24-32. doi: 10.1016/j.ejphar.2017.07.039.
Pastorova V.E., Liapina L.A., Alshmarin I.P., Ostrovskaia P.U., Gudasheva T.A., Lugovskoĭ E.V. Fibrin-depolymerization activity and the antiplatelet effect of small cyclic and linear proline-containing peptides // Izv Akad Nauk Ser Biol. - 2001. - N. 5. - P. 593-6.
Lyapina L.A., Pastorova V.E., Obergan T.Y. Changes in hemostatic parameters after intranasal administration of peptide Pro-GlyPro // Bull Exp Biol Med. -2007. - V. 144, N 4. - P. 491-3. doi: 10.1007/s10517-007-0358-6.
Liapina L.A., Grigor’eva M.E., Andreeva L.A., Miasoedov N.F. Protective antithrombotic effects of proline-containing peptides in the animal body subjected to stress // Izv Akad Nauk Ser Biol. -2010. - N 4. - P. 462-7.
Shevchenko K.V., Nagaev I.Y., Andreeva L.A., Shevchenko V.P., Myasoedov N.F. Stability of prolin-containing peptides in biological media // Biomed Khim. - 2019. - V. 65, N 3. - P. 180- 201. doi: 10.18097/PBMC20196503180.
Wang Z., Zhang S., Jin H., Wang W., Huo J., Zhou L., Wang Y., Feng F., Zhang L. Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based pharmacophore generation // Eur J Med Chem. - 2011. - V. 46, N 8. - P. 3428-33. doi: 10.1016/j. ejmech.2011.05.007.
Montezano A.C., Nguyen Dinh Cat A., Rios F.J., Touyz R.M. Angiotensin II and vascular injury // Curr Hypertens Rep. -2014. - V. 16, N 6. - P. 431. doi: 10.1007/s11906-014-0431-2.

补充文件

附件文件

动作

1. JATS XML

下载

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

11-amino acid peptide imitating the structure of erythropoietin α-helix b improves endothelial function, but stimulates thrombosis in rats.

全文:

详细

关键词

全文:

作者简介

M. Korokin

V. Soldatov

A. Tietze

M. Golubev

A. Belykh

M. Kubekina

O. Puchenkova

T. Denisyuk

V. Gureyev

T. Pokrovskaya

O. Gudyrev

M. Zhuchenko

M. Zatolokina

M. Pokrovskiy

参考

补充文件